ArticleScientific reports2026
BigEye: a clinically interpretable deep learning framework for diabetic retinopathy detection and stage prediction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Diabetic Retinopathy (DR) is a major cause of vision loss and blindness in diabetic individuals. DR is conventionally diagnosed by assessing retinal lesion findings from fundus photographs taken during exams and applying a scale like International Classification of Diabetic Retinopathy (ICDR). The expected rise in future DR cases highlights the need for deep learning models capable of identifying relevant lesions and delivering explainable results. To this end we present BigEye, a novel framework that uses extracted lesion features to predict ICDR stage. A dataset of fundus images from a local hospital and a public dataset, annotated with segmentation masks and DR stages, is assembled to train a DeepLabV3 + model on six retinal lesions. Lesion quantities and pixel area features are integrated by a classifier model evaluated through 10-fold nested cross validation (0.77 ± 0.07 precision, 0.71 ± 0.06 recall, 0.72 ± 0.07 F1 score, 0.95 ± 0.02 ROC-AUC, 0.83 ± 0.03 accuracy). A Shapely Additive Explanations (SHAP) value analysis notably shows close alignment between discriminative lesions for each DR stage and corresponding ICDR stage criteria. These results demonstrate that BigEye is well suited for providing explainable ICDR stage predictions grounded in clinical knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.